Meda’s rights issue oversubscribed

• 11,592,196 shares, corresponding to 99.84 per cent of the offered shares, have been subscribed through exercise of subscription rights

• Including the shares that have been subscribed for without preferential rights, the rights issue has been oversubscribed by approximately 56 per cent

• The issue generated SEK 1,858 million before issue costs

11,592,196 shares, corresponding to 99.84 per cent of the offered shares, have been subscribed through exercise of subscription rights in Meda’s rights issue. Including the shares that have been subscribed for without preferential rights, the rights issue has been oversubscribed by approximately 56 per cent. The issue generated SEK 1,858 million, before issue costs.

The 18,288 shares that have not been subscribed for through exercise of subscription rights, corresponding to 0.16 per cent of the total number of offered shares, will be allotted to those shareholders who subscribed for shares without preferential rights in accordance with principles set forth in the prospectus.

Through the rights issue the number of shares in Meda increases by 11,610,484 shares and the share capital increases by SEK 23,220,968. After the rights issue the total number of shares in Meda amounts to 116,104,842 shares and the share capital to SEK 232,209,684. The last trading day with the paid-up subscribed shares (BTA) is expected to be 20 February 2007. The newly issued shares are expected to be traded on the Stockholm Stock Exchange (Stockholmsbörsen) starting Thursday, 1 March 2007.

”The acquisition of 3M’s European pharmaceutical division positions Meda as a leading European specialty pharma company. It is very gratifying that the company’s shareholders have confidence in our further build-up” says Anders Lönner, CEO of Meda.

SEB Enskilda is acting as financial advisor to Meda AB for the rights issue.

Solna, Sweden, 13 February 2007
Meda AB (publ)

About Us

Meda is one of Europe's leading specialty pharma companies, with focus on marketing and market-adapted product development. Long-term partnerships and acquisitions are fundamental factors in its strategy.

Subscribe

Documents & Links